TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Radiopharm Theranostics Limited ( (AU:RAD) ).
Radiopharm Theranostics Limited has announced the appointment of Bruce Goodwin as a director, effective from November 19, 2025. The initial director’s interest notice indicates that Bruce Goodwin currently holds no securities or interests in the company, which may suggest a neutral impact on the company’s immediate financial operations or market perception.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on developing radiopharmaceutical products for diagnostic and therapeutic purposes. The company is listed on the Australian Securities Exchange under the ticker RAD.
Average Trading Volume: 6,592,237
Technical Sentiment Signal: Sell
Current Market Cap: A$61.17M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.